Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 6.4% – Time to Sell?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) fell 6.4% during trading on Friday . The stock traded as low as $59.55 and last traded at $59.52. 309,504 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 610,010 shares. The stock had previously closed at $63.60.

Analyst Ratings Changes

Several research firms have recently commented on ORKA. Stifel Nicolaus raised their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Piper Sandler started coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price for the company. Barclays increased their price target on shares of Oruka Therapeutics from $50.00 to $78.00 and gave the company an “overweight” rating in a report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $64.90.

Oruka Therapeutics Stock Performance

The company’s fifty day simple moving average is $39.02 and its two-hundred day simple moving average is $31.78. The stock has a market capitalization of $2.96 billion, a PE ratio of -32.18 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. Sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the sale, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 23,765 shares of company stock valued at $849,575. Insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ORKA. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics during the first quarter valued at approximately $2,505,000. JPMorgan Chase & Co. lifted its position in shares of Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after purchasing an additional 13,115 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics during the second quarter worth $28,000. Rhumbline Advisers acquired a new position in shares of Oruka Therapeutics during the second quarter worth $320,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Oruka Therapeutics during the second quarter worth $96,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.